Syniverse and Telefónica Collaborate to Offer New Secure Global Messaging Service
28.10.2019 10:05:00 EET | Business Wire | Press release
At the GSMA WAS#10 conference and exposition, Syniverse, the world’s most connected company, announced it is developing a secure global messaging solution that is designed to help brands keep text messaging clear of inherent security risks that come when sending messages over the internet and without proper user authentication.
To protect against vulnerabilities in text messaging, Syniverse is collaborating with Telefónica to offer businesses a global cloud-based messaging platform that runs over a private network with end-to-end encryption of actual messages and messages in transit. The network operates separately from the public internet using private addressing schemes that make it invisible to those with malicious intent.
What used to be considered “secure enough” for text messaging is no longer adequate for keeping information safe from the advanced techniques of fraudsters and hackers. That’s why companies like Telefónica International in Latin America and Europe are turning to Syniverse to help manage mobile communications by confirming customer identity and consent, and securely transmitting customer and business data.
The mobile attack rate in Latin America, where the Syniverse solution will initially launch, is 8.9 percent, according to Lexis Nexis. Payment transactions, logins and new account creations are being targeted by fraudulent bots, and by the spoofing of internet protocol (IP) addresses, devices and identities. With this secure global messaging solution, Syniverse and Telefónica will protect customers and mobile operators from these attacks as well as an array of other cyberattacks, including phishing, whaling, denial-of-service, and man-in-the-middle incidents.
Latin America isn’t the only region that’s targeted by malicious actors. In the U.S. last year, there were 16.7 million people affected by account takeover fraud, according to Javelin Research. In one case, a leading bank lost $15 million in fraudulent withdrawals due to poor transport, application and security encryptions. Attackers fraudulently assumed the identity of one of the bank’s customers to access the payment network before making fake withdrawals from multiple bank branches.
The need for the secure alternative that Syniverse will offer extends beyond the banking industry. The potential for loss affects any company that relies on digital communications. Text messages can be hacked to access financial or operational information or even to control networks, systems and databases. Whether it’s an e-commerce platform that sends one-time password texts to authenticate customers or a government agency deploying surveillance drones, a variety of processes used by different industries are at risk.
Syniverse will safeguard the customer experience and drastically decrease business risks by offering full-network-layer encryption all the way through a company application to the mobile operator with segmenting isolation in two areas. Also, automated alarming will set off if network end points deviate from expected communications behavior.
Product availability will be based on the number of mobile network operators connected to the secure global messaging solution, which will continually expand. Companies looking to secure their communications can contact Syniverse here.
CLICK TO TWEET : .@Syniverse & @telefonicab2b collaborate to make #textmessaging safer from hackers and fraudsters #enterprises. #cybersecurity #fraud @GSMA #WAS10 http://ow.ly/ZT8q50wUcpQ
Quote
- John Wick, Senior Vice President and General Manager, Global Product, Syniverse
“Any device that is capable of sending and receiving text messages over an unsecured network is at risk of cyberattack. To minimize this risk, Syniverse and Telefónica are leading the way to secure the messaging environment so that sensitive information is protected at each stage of its journey as a message is sent from a brand, passed through a mobile network, and received by an end device.”
Supporting Resources
- Read about GSMA WAS#10.
- Read about Telefónica.
- Read about Syniverse.
- Read about Syniverse secure global messaging solution.
- Read about John Wick.
- Read and subscribe to Syniverse Blog.
- Read and subscribe to Syniverse news releases.
- For more information about Syniverse’s news and activities, and follow the company on Twitter, LinkedIn and Facebook.
About Syniverse
Syniverse is the world’s most connected company – we pioneer innovations that take business further. Our secure, global network reaches billions of people and devices. Our engagement platform powers the customized experiences of the future. And the millions of secure transactions we drive every minute are revolutionizing how goods and services are exchanged. We have always led companies to reimagine the boundaries of possibility. Today we’re delivering on opportunities with the power to change the world.
About Telefonica Business Solutions
Telefónica Business Solutions a leading provider of a wide range of integrated communication solutions for the B2B market, manages globally the Enterprise (Large Enterprise and SME), MNC (Multinational Corporations), Wholesale (fixed and mobile carriers, ISPs and content providers) and Roaming businesses within the Telefónica Group. Business Solutions develops an integrated, innovative and competitive portfolio for the B2B segment including digital solutions (Big Data, Cloud, IoT or Security) and telecommunication services (international voice, IP, bandwidth capacity, satellite services, mobility, integrated fixed, mobile, IT services and global solutions). Telefonica Business Solutions is a multicultural organization, working in over 40 countries and with service reach in over 170 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191028005117/en/
Contact information
Kevin Petschow
Syniverse
+1.813.637.5084
kevin.petschow@syniverse.com
Matt Burrows
The Hoffman Agency (for Syniverse)
+1.408.286.2611
mburrows@hoffman.com
Telefónica
Corporate Communications Department
+34 91 482 3800
prensatelefonica@telefonica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
